Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?

Musto, Pellegrino

doi:10.1634/theoncologist.2018-0097

Cited by 4 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further issues remain to be better addressed regarding MoAbs currently approved and those near to be introduced in the clinical practice for MM [124]. Among the most important ones is the choice of appropriate MoAbs in different clinical conditions, their optimal combinations, timing (i.e.…”

Section: Expert Opinionmentioning

confidence: 99%

Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses

Musto

Rocca

2020

Expert Review of Hematology

Self Cite

View full text Add to dashboard Cite

Introduction: In the last few years, monoclonal antibodies have rapidly modified the therapeutic strategies for treating patients with multiple myeloma. Areas covered: In this review, the most recent literature data regarding indications for which monoclonal antibodies are currently or will be shortly approved as salvage therapies in relapsed/refractory myeloma are discussed. In particular, updated results until March 22, 2020 of antibodies directed against CD38 (daratumumab and isatuximab), SLAMF7 (elotuzumab), BCMA (GSK2857916/belantamab mafodotin), and PD-1/PD-1 L axis (nivolumab and pembrolizumab) will be analyzed in detail. Expert opinion: Monoclonal antibodies represent a new, very effective approach that will open novel and dynamic treatment scenarios for myeloma patients in the coming years. Optimal positioning and selection of different antibodies that are or will be soon available, appropriate combinations and careful evaluation of possible new toxicities should be considered in the future management of these patients.

show abstract

Section: Expert Opinionmentioning

confidence: 99%